A shared report on doctors turning to GLP-1 medications for weight loss in some kids. Details are thin, so tap through for the full story.
Recap by typeshit. Post by Facebook on Facebook.
TIKR points to retatrutide, due for filing in early 2027, and says a pending Seventh Circuit ruling on whether it counts as a biologic could decide 5 vs 12 years of exclusivity.
She lost 7 kilos in her first month, regained it during a month-long break, and now says she's eating more and gaining in week two back.
The author, who holds Novo shares, cites Morgan Stanley's $190 billion obesity market forecast for 2035 and an NIH-funded mouse study on aging.
The chain says it is exploring concepts including grilled items aimed at GLP-1 users, a sign of how the drugs are shifting food businesses.
New Zealand's cardiovascular advisory committee rated it a high priority. Wegovy is used there now but patients pay the full cost themselves.
Twelve Novo abstracts head to Denver, including a 5,000-patient records study comparing semaglutide and resmetirom, plus four on efruxifermin.
Loading…